Business Description
Rani Therapeutics Holdings Inc
NAICS : 541713
SIC : 2833
ISIN : US7530181004
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.88 | |||||
Equity-to-Asset | 0.07 | |||||
Debt-to-Equity | 12.43 | |||||
Debt-to-EBITDA | -0.65 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -41.9 | |||||
3-Year FCF Growth Rate | -33.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 17.94 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 43.44 | |||||
9-Day RSI | 47.23 | |||||
14-Day RSI | 47.99 | |||||
6-1 Month Momentum % | -66.14 | |||||
12-1 Month Momentum % | 10.2 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.93 | |||||
Quick Ratio | 1.93 | |||||
Cash Ratio | 1.86 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.6 | |||||
Shareholder Yield % | -8.02 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -236.18 | |||||
ROA % | -49.47 | |||||
ROIC % | -364.6 | |||||
3-Year ROIIC % | -1164.63 | |||||
ROC (Joel Greenblatt) % | -621.97 | |||||
ROCE % | -107.23 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 21.82 | |||||
Price-to-Tangible-Book | 20.82 | |||||
EV-to-EBIT | -1.45 | |||||
EV-to-Forward-EBIT | -1.14 | |||||
EV-to-EBITDA | -1.47 | |||||
EV-to-Forward-EBITDA | -1.15 | |||||
EV-to-FCF | -1.74 | |||||
Earnings Yield (Greenblatt) % | -68.97 | |||||
FCF Yield % | -60.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RANI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Rani Therapeutics Holdings Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -1.18 | ||
Beta | -0.02 | ||
Volatility % | 142.91 | ||
14-Day RSI | 47.99 | ||
14-Day ATR ($) | 0.313403 | ||
20-Day SMA ($) | 2.40825 | ||
12-1 Month Momentum % | 10.2 | ||
52-Week Range ($) | 1.82 - 8.75 | ||
Shares Outstanding (Mil) | 32.49 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 0 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Rani Therapeutics Holdings Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Rani Therapeutics Holdings Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Rani Therapeutics Holdings Inc Frequently Asked Questions
What is Rani Therapeutics Holdings Inc(RANI)'s stock price today?
When is next earnings date of Rani Therapeutics Holdings Inc(RANI)?
Does Rani Therapeutics Holdings Inc(RANI) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |